Effect of anlotinib on serum tumor markers and tumor-associated growth factors in patients with stage Ⅳ non-small cell lung cancer after progression of first-line therapy
Objective To investigate the effect of anlotinib on serum tumor markers and tumor-associated growth factors in patients with stage Ⅳ non-small cell lung cancer(NSCLC)after first-line treatment.Methods A total of 102 patients with stageⅣ NSCLC who had developed first-line treatment were selected and randomly divided,with 51 cases in the control group given docetaxel chemotherapy,and 51 cases in the observation group given docetaxel combined with anlotinib.The clinical efficacy,serum tumor markers,and related growth factor levels and adverse reaction were compared between the two groups.Results Af-ter the treatment,the serum levels of tumor markers CyFRA21-1 and carcinoembryonic antigen(CEA)in the observation group were lower than those in the control group(P＜0.05).After the treatment,the levels of vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)in the observation group were lower than those in the control group(P＜0.05).The clinical efficacy of the observation group was higher than that of the control group(P＜0.05).There was no significant difference in side effects between the two groups(P＞0.05).Conclusion Anlotinib has a significant effect on patients with stage Ⅳ NSCLC after first-line treatment,which can reduce the level of serum tumor markers,inhibit tumor angiogenesis,and has high safety.
国家科技期刊平台
NSTL
万方数据
